Skip to content

Trial Summary

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Carboplatin And Etoposide With Or Without Tiragolumab (Anti-Tigit Antibody) In Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Acronym:

SKYSCRAPER-02

ACTRN/NCT /ethics:

NCT04256421

Scientific title:

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC).

Sponsor / Cooperative group:

Hoffmann-La Roche

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream ES-SCLC
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2020-02-04
Anticipated End Date2023-09-29

Participating Hospitals

HospitalLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Emailandy.phay@sa.gov.au
Phone08 8282 0833
Principal InvestigatorDr Dainik Patel
Recruitment StatusRecruiting